Progenics Pharmaceuticals Inc.

Cheshire, CT, United States

Progenics Pharmaceuticals Inc.

Cheshire, CT, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Progenics Pharmaceuticals Inc. | Date: 2017-02-08

This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use.


Patent
Progenics Pharmaceuticals Inc. | Date: 2017-09-20

This invention relates to pharmaceutical compositions containing R-MNTX, a chelating agent and a buffer. Such compositions my be useful for the treatment of an opioid incuced side effect in a patient, in particular constipation.


Patent
Progenics Pharmaceuticals Inc. and Wyeth LLC | Date: 2016-09-07

The present invention provides a compound of formula I:^(1), R^(2), R^(2) and X^(-) are as defined and described herein, and compositions thereof, useful as peripheral mu opioid receptor antagonists.


Patent
Progenics Pharmaceuticals Inc. and Wyeth Llc | Date: 2015-08-07

The present invention provides a new forms of (R)N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist.


Patent
Progenics Pharmaceuticals Inc. | Date: 2015-03-09

Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.


Patent
Progenics Pharmaceuticals. Inc. | Date: 2013-06-06

This invention relates to synthesis of (R),(R)-2,2-bis-MNTX, as shown in Formula (I), and related methods and products.


Patent
Progenics Pharmaceuticals Inc. | Date: 2014-03-18

This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use.


Patent
Progenics Pharmaceuticals Inc. | Date: 2014-05-14

This invention relates to synthesis of (R),(R)2_(,)2-bis-MNTX, as shown in Formula (1), and related methods and products.


Patent
Progenics Pharmaceuticals Inc. | Date: 2013-12-13

The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.


Patent
Progenics Pharmaceuticals Inc. | Date: 2015-06-22

This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use.

Loading Progenics Pharmaceuticals Inc. collaborators
Loading Progenics Pharmaceuticals Inc. collaborators